Business Context and Reporting Period
Company: Pavmed Inc. (PAVM)
Filing Type: Form 8-K (Current Report)
Date of Report: April 30, 2020
Event: Entry into a Material Definitive Agreement and unregistered sale of equity-linked securities.
Key Financial Metrics and Transaction Details
This filing details a private placement of debt rather than a standard quarterly financial report. Key transaction metrics include:
- New Debt Instrument: Senior Convertible Note with an initial principal amount of $4,111,111.
- Gross Proceeds: $3,700,000 (sold with a $411,111 original issue discount).
- Net Proceeds: Approximately $3,579,750 after deducting a $120,250 advisory fee and estimated expenses.
- Interest Rate: 7.875% per annum (increases to 18.0% per annum upon an Event of Default).
- Conversion Price: $5.00 per share (subject to adjustment).
- Maturity Date: April 30, 2022.
- Existing Debt: Prior Convertible Notes (2018 and 2019 issuances) have an outstanding principal balance of $14,050,000.
- Liquidity Covenant: The company must maintain available cash of $1,750,000 at the end of each fiscal quarter.
Material Changes and Waivers
The transaction resulted in significant modifications to the terms of the company's existing debt obligations:
- Waivers on Prior Notes: The investor waived penalties related to the delayed effectiveness of a registration statement for the 2019 Convertible Notes.
- Capital Raise Waiver: The requirement to complete a non-dilutive capital raise of $9,000,000 was waived.
- Conversion Price Reduction: The conversion price of the 2019 Convertible Notes was voluntarily reduced to $1.48 per share (subject to board approval and a cap of $756,757 in principal converted at this rate).
- Stockholder Approval Deadline: Extended to July 31, 2020, to approve an increase in authorized shares from 100 million to 150 million.
Outlook, Risks, and Covenants
Management Commentary and Covenants:
- Issuance Restrictions: The company cannot issue equity or equity-linked securities below $5.00 per share until the later of six months post-closing or when less than $700,000 of the new note remains outstanding.
- Variable Rate Prohibition: The company is prohibited from entering into variable rate transactions while the note is outstanding.
- Redemption Rights: The note includes various redemption triggers, including Change of Control, subsequent equity placements, and holder optional redemption starting October 30, 2020. Redemption prices generally equal 115% of the outstanding principal plus accrued interest.
- Events of Default: Include breach of financial covenants and the failure of the CEO (Lishan Aklog, M.D.) or CFO (Dennis McGrath) to serve as officers.
- Participation Rights: The investor received rights to participate in up to 100% of future equity offerings for three years.
Risks: The filing does not provide specific forward-looking revenue or profit guidance. The primary risks identified are the high cost of capital (interest rates and OID), dilution potential upon conversion, and strict covenants regarding cash maintenance and executive retention.
Investor Verification Checklist
- Verify the company's current cash balance to ensure compliance with the $1,750,000 quarterly liquidity covenant.
- Confirm the status of the stockholder meeting scheduled for July 31, 2020, regarding the increase in authorized shares.
- Monitor the conversion price of the 2019 Convertible Notes ($1.48) and the potential dilution impact if the $756,757 cap is utilized.
- Review the total outstanding debt load, now exceeding $18 million ($14.05M prior + $4.11M new), against the company's cash burn rate.
- Check for any subsequent equity issuances that might trigger the investor's participation rights or redemption rights.